1,614 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Bought by SkyOak Wealth LLC

SkyOak Wealth LLC bought a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,614 shares of the company’s stock, valued at approximately $243,000.

Several other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in shares of TransMedics Group by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 1,889,094 shares of the company’s stock valued at $139,680,000 after acquiring an additional 23,979 shares during the last quarter. Eventide Asset Management LLC grew its holdings in TransMedics Group by 7.4% during the fourth quarter. Eventide Asset Management LLC now owns 994,240 shares of the company’s stock valued at $78,475,000 after purchasing an additional 68,884 shares during the last quarter. First Light Asset Management LLC raised its position in shares of TransMedics Group by 22.0% in the fourth quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock valued at $59,538,000 after purchasing an additional 136,217 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of TransMedics Group by 3.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 730,010 shares of the company’s stock worth $53,977,000 after buying an additional 21,737 shares during the last quarter. Finally, Wasatch Advisors LP bought a new stake in shares of TransMedics Group during the 1st quarter worth $32,162,000. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Stock Down 0.1 %

TMDX opened at $155.96 on Thursday. The company has a market capitalization of $5.14 billion, a P/E ratio of -458.71 and a beta of 1.99. The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48. The firm’s fifty day moving average price is $154.75 and its two-hundred day moving average price is $128.18. TransMedics Group, Inc. has a fifty-two week low of $36.42 and a fifty-two week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.14. The business had revenue of $114.30 million for the quarter, compared to analyst estimates of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The firm’s revenue was up 117.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.03) EPS. On average, analysts anticipate that TransMedics Group, Inc. will post 1.23 EPS for the current year.

Insider Activity at TransMedics Group

In other TransMedics Group news, insider Anil P. Ranganath sold 4,289 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $152.20, for a total transaction of $652,785.80. Following the completion of the transaction, the insider now directly owns 8,893 shares in the company, valued at $1,353,514.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other TransMedics Group news, insider Anil P. Ranganath sold 4,289 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $152.20, for a total value of $652,785.80. Following the transaction, the insider now directly owns 8,893 shares in the company, valued at $1,353,514.60. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $8,948,714.31. The disclosure for this sale can be found here. Insiders have sold a total of 61,247 shares of company stock valued at $9,650,880 in the last 90 days. 7.00% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages recently commented on TMDX. Cantor Fitzgerald assumed coverage on shares of TransMedics Group in a report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 target price on the stock. Piper Sandler boosted their price objective on TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Oppenheimer raised their target price on TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. Morgan Stanley upped their price target on TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Finally, Stephens raised their price objective on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $171.44.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.